125 related articles for article (PubMed ID: 11912151)
1. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.
Thirdborough SM; Radcliffe JN; Friedmann PS; Stevenson FK
Cancer Res; 2002 Mar; 62(6):1757-60. PubMed ID: 11912151
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma.
Wong CP; Levy R
Cancer Res; 2000 May; 60(10):2689-95. PubMed ID: 10825142
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.
Spellerberg MB; Zhu D; Thompsett A; King CA; Hamblin TJ; Stevenson FK
J Immunol; 1997 Aug; 159(4):1885-92. PubMed ID: 9257853
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic regulatory responses induced by vaccination with DNA encoding murine TCR Valpha5 and Vbeta2.
Wu Y; Zhang Y; Xu X; Lv P; Gao X
Cell Mol Immunol; 2007 Aug; 4(4):287-93. PubMed ID: 17764619
[TBL] [Abstract][Full Text] [Related]
5. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.
King CA; Spellerberg MB; Zhu D; Rice J; Sahota SS; Thompsett AR; Hamblin TJ; Radl J; Stevenson FK
Nat Med; 1998 Nov; 4(11):1281-6. PubMed ID: 9809552
[TBL] [Abstract][Full Text] [Related]
6. DNA fusion gene vaccines against cancer: from the laboratory to the clinic.
Stevenson FK; Rice J; Ottensmeier CH; Thirdborough SM; Zhu D
Immunol Rev; 2004 Jun; 199():156-80. PubMed ID: 15233733
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study on TCRbeta idiotypic antigenic determinants DNA vaccine to induce anti-lymphoma antibodies].
Zhang Y; Zhu P; Shi Y; Liu J; Pu D; Cao X; Zhu Q; Wang Y; Ma M; Yu J
Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):68-72. PubMed ID: 12015073
[TBL] [Abstract][Full Text] [Related]
8. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
Savelyeva N; King CA; Vitetta ES; Stevenson FK
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
[TBL] [Abstract][Full Text] [Related]
10. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.
Savelyeva N; Munday R; Spellerberg MB; Lomonossoff GP; Stevenson FK
Nat Biotechnol; 2001 Aug; 19(8):760-4. PubMed ID: 11479570
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
13. [In vivo study of antitumor immune responses induced by anti-idiotypic minibody vaccine of ovarian cancer].
Chang XH; Cui H; Feng J; Yang WL; Li Y; Fu TY
Ai Zheng; 2004 Jul; 23(7):777-81. PubMed ID: 15248911
[TBL] [Abstract][Full Text] [Related]
14. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.
Forconi F; King CA; Sahota SS; Kennaway CK; Russell NH; Stevenson FK
Immunology; 2002 Sep; 107(1):39-45. PubMed ID: 12225361
[TBL] [Abstract][Full Text] [Related]
15. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy.
Abe A; Emi N; Taji H; Kasai M; Kohno A; Saito H
Gene Ther; 1996 Nov; 3(11):988-93. PubMed ID: 8940639
[TBL] [Abstract][Full Text] [Related]
16. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
17. TCR vaccines for active immunotherapy of T cell malignancies.
Okada CY; Wong CP; Denney DW; Levy R
J Immunol; 1997 Dec; 159(11):5516-27. PubMed ID: 9548492
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
[TBL] [Abstract][Full Text] [Related]
19. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
Syrengelas AD; Levy R
J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
